Risk Assessment of Computer-Aided Diagnostic Software for Hepatic Resection

• Published in: IEEE transactions on radiation and plasma medical sciences Vol. 6; no. 6; pp. 667 - 677
• Main Authors: Akhtar, Yusuf, Dakua, Sarada Prasad, Abdalla, Alhusain, Aboumarzouk, Omar Mousa, Ansari, Mohammed Yusuf, Abinahed, Julien, Elakkad, Mohamed Soliman Mohamed, Al-Ansari, Abdulla
• Format: Journal Article
• Language: English
• Published: Piscataway IEEE 01.07.2022; The Institute of Electrical and Electronics Engineers, Inc. (IEEE)
• Subjects: Algorithms; Bevacizumab; Computer-aided detection or diagnostic (CAD); Diagnostic software; hepatic resection (HR); Liver; Mathematical model; Medical diagnosis; Monoclonal antibodies; Parameters; Plasmas; recurrence after HR; Risk assessment; Simulation; Software; Solid modeling; Statistical distributions; Surgery; surgical margin (SM); Targeted cancer therapy; Tumors
• ISSN: 2469-7311; 2469-7303
• DOI: 10.1109/TRPMS.2021.3071148

In this article, we study the indirect relationship between the adoption of computer-aided detection or diagnostic (CADe or CADx) systems for hepatic resection (HR) and the patient's health post-surgery. We vary the number, actual size, and the estimated size of tumors along with model parameters of tumor growth over 1000 simulations of HR according to predefined statistical distributions of parameter values. The average time (<inline-formula> <tex-math notation="LaTeX">t </tex-math></inline-formula>) taken by the tumors to relapse is assessed for the nonadoption of computer-aided detection or diagnostic (CAD) (case 1), the adoption of semiautomatic CAD (case 2), and the adoption of automatic CAD (case 3) in HR. In this study, we have simulated 126 automatic CAD algorithms (case 3). For tumor volumes (TV) less than 50 cm 3 , if administration of bevacizumab, a post-operative therapy, is (not) adopted in the simulation, <inline-formula> <tex-math notation="LaTeX">t </tex-math></inline-formula> is found to be 646, 84, and 60 days (40, 24, and 17 days) for case 1, case 2, and case 3, respectively. For TV greater than 50 cm 3 , and with (without) bevacizumab, <inline-formula> <tex-math notation="LaTeX">t </tex-math></inline-formula> is found to be 86, 1, and 6 days (28, 6, and 3 days) for case 1, case 2, and case 3, respectively. For with (without) bevacizumab treatment and for all tumor volumes, <inline-formula> <tex-math notation="LaTeX">t </tex-math></inline-formula> is found to be 260, 90, and 104 days (38, 13, and 11 days) for case 1, case 2, and case 3, respectively. We have observed that the tumors relapsed quickly in those cases where CAD was adopted.